News
Click here for news in Danish.
December 31, 2019 | Company Announcements
Bavarian Nordic Announces Closing of Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKline and Updates Year-end Cash PreparednessDecember 17, 2019 | Company Announcements
Bavarian Nordic Announces the Sale of Priority Review VoucherDecember 13, 2019 | Company Announcements
Bavarian Nordic Receives Antitrust Clearance for Acquisition of Rabipur/RabAvert and Encepur from GlaxoSmithKlineDecember 09, 2019 | Press Releases
Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakNovember 27, 2019 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Extraordinary General Meeting, held November 27, 2019November 14, 2019 | Press Releases
Phase 3 Results of Bavarian Nordic’s Smallpox Vaccine Published in The New England Journal of Medicine November 13, 2019 | Company Announcements
Bavarian Nordic Announces Appointment of Jean-Christophe May as Executive Vice President and Chief Commercial OfficerNovember 11, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 3 Lot-Consistency Trial of Freeze-dried Smallpox VaccineNovember 07, 2019 | Company Announcements
Bavarian Nordic Announces Submission of European Marketing Authorisation Applications for Investigational Ebola Vaccine RegimenNovember 07, 2019 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 07, 2019 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2019November 06, 2019 | Press Releases
Recent Advances in Bavarian Nordic’s Cancer Immunotherapy Platform Published in Nature CommunicationsOctober 31, 2019 | Press Releases
Investigational Ebola Vaccine from Janssen and Bavarian Nordic to Support Outbreak Response in Democratic Republic of the CongoOctober 25, 2019 | Company Announcements
Bavarian Nordic A/S – Notice Convening Extraordinary General Meeting October 21, 2019 | Company Announcements
Bavarian Nordic Announces a Transformative Acquisition of Two Established Commercial Vaccines from GlaxoSmithKlineOctober 18, 2019 | Company Announcements
Bavarian Nordic Updates on Phase 2 Study of CV301 in Bladder Cancer October 08, 2019 | Company Announcements
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine October 03, 2019 | Press Releases
Bavarian Nordic Completes Enrollment of Phase 2 Trial in Chordoma PatientsSeptember 24, 2019 | Company Announcements
Bavarian Nordic Announces U.S. FDA Approval of JYNNEOS™ (Smallpox and Monkeypox Vaccine, Live, Non-replicating) for Prevention of Smallpox and Monkeypox Disease in AdultsAugust 29, 2019 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise August 15, 2019 | Company Announcements
Bavarian Nordic Announces First Half 2019 Results June 25, 2019 | Press Releases
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsJune 19, 2019 | Company Announcements
Bavarian Nordic Initiates Phase 3 Trial of Freeze-dried MVA-BN® Smallpox VaccineJune 06, 2019 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise June 05, 2019 | Company Announcements
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma